Article,

Stabilization of desmoglein-2 binding rescues arrhythmia in arrhythmogenic cardiomyopathy

, , , , , , , , , and .
JCI Insight, (2020)Schinner, Camilla Erber, Bernd Markus Yeruva, Sunil Schlipp, Angela Rotzer, Vera Kempf, Ellen Kant, Sebastian Leube, Rudolf E Mueller, Thomas D Waschke, Jens eng Research Support, Non-U.S. Gov't 2020/05/08 JCI Insight. 2020 May 7;5(9):e130141. doi: 10.1172/jci.insight.130141..
DOI: 10.1172/jci.insight.130141

Abstract

Arrhythmogenic cardiomyopathy (AC) is a genetic disease causing arrhythmia and sudden cardiac death with only symptomatic therapy available at present. Mutations of desmosomal proteins, including desmoglein-2 (Dsg2) and plakoglobin (Pg), are the major cause of AC and have been shown to lead to impaired gap junction function. Recent data indicated the involvement of anti-Dsg2 autoantibodies in AC pathogenesis. We applied a peptide to stabilize Dsg2 binding similar to a translational approach to pemphigus, which is caused by anti-desmoglein autoantibodies. We provide evidence that stabilization of Dsg2 binding by a linking peptide (Dsg2-LP) is efficient to rescue arrhythmia in an AC mouse model immediately upon perfusion. Dsg2-LP, designed to cross-link Dsg2 molecules in proximity to the known binding pocket, stabilized Dsg2-mediated interactions on the surface of living cardiomyocytes as revealed by atomic force microscopy and induced Dsg2 oligomerization. Moreover, Dsg2-LP rescued disrupted cohesion induced by siRNA-mediated Pg or Dsg2 depletion or l-tryptophan, which was applied to impair overall cadherin binding. Dsg2-LP rescued connexin-43 mislocalization and conduction irregularities in response to impaired cardiomyocyte cohesion. These results demonstrate that stabilization of Dsg2 binding by Dsg2-LP can serve as a novel approach to treat arrhythmia in patients with AC.

Tags

Users

  • @jvsi_all

Comments and Reviews